TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
MARKET INSIGHTS
The global Sodium Iodine (131I) Drugs market size was valued at USD 28.2 million in 2024. The market is projected to grow from USD 30.2 million in 2025 to USD 45.1 million by 2032, exhibiting a CAGR of 7.1% during the forecast period.
Sodium Iodide I-131 is a crucial radiopharmaceutical agent primarily used for the diagnosis and treatment of thyroid disorders. This therapeutic compound is selectively taken up by the thyroid gland, where it delivers localized radiation. Its primary applications include the treatment of hyperthyroidism and certain types of thyroid cancer.
This market operates within the broader pharmaceutical industry, which was valued at USD 1,475 billion in 2022. While the overall pharmaceutical market is growing at a CAGR of 5%, the Sodium Iodine (131I) Drugs segment is experiencing a higher growth trajectory. This is largely driven by the rising global prevalence of thyroid diseases, increased investment in nuclear medicine, and ongoing technological advancements in radiopharmaceuticals. However, the sector faces significant challenges, including stringent regulatory hurdles for radioactive materials and the high costs associated with research, development, and specialized manufacturing processes.
Rising Global Prevalence of Thyroid Disorders to Propel Market Expansion
The escalating incidence of thyroid conditions worldwide is a primary engine for the Sodium Iodine (131I) Drugs market. Hyperthyroidism and thyroid cancer represent significant public health burdens, with an estimated over 200 million people globally suffering from some form of thyroid disorder. Thyroid cancer incidence rates have been steadily increasing, with a documented rise of approximately 3% annually in many regions over the past decade. This growing patient pool directly translates into heightened demand for effective diagnostic and therapeutic solutions. Sodium Iodide I-131 remains a cornerstone in the management of these conditions, offering a non-invasive treatment option for hyperthyroidism and a targeted therapy for ablating residual thyroid tissue post-thyroidectomy in cancer patients. The reliability and well-established efficacy profile of this radiopharmaceutical make it an indispensable tool in nuclear medicine departments globally.
Advancements in Nuclear Medicine Infrastructure to Fuel Adoption
Significant investments and technological progress in nuclear medicine infrastructure are accelerating the adoption of radiopharmaceuticals like Sodium Iodine (131I). The global number of PET/CT and SPECT scanners has seen substantial growth, facilitating broader access to diagnostic and therapeutic nuclear medicine procedures. Governments and private healthcare providers are channeling funds into modernizing healthcare facilities; for instance, capital investments in medical imaging equipment in emerging economies have grown at a CAGR of over 6% in recent years. This expansion allows for more precise diagnosis and treatment planning for thyroid diseases, creating a conducive environment for the utilization of I-131 therapies. The integration of advanced imaging with targeted radionuclide therapy represents a paradigm shift towards more personalized and effective patient care.
Furthermore, the development of compact cyclotrons and improved radiopharmacy networks enhances the reliable supply chain for these critical drugs.
➤ For instance, regulatory pathways for orphan drugs and radiopharmaceuticals have been streamlined in several key markets, expediting the approval process for new formulations and ensuring patient access to essential therapies.
Moreover, increasing healthcare expenditure, which surpassed 10% of GDP in many developed nations, underscores the financial commitment to incorporating advanced treatments like I-131 therapy into standard care protocols.
Stringent Regulatory and Logistical Hurdles to Impede Market Growth
The production, transportation, and administration of Sodium Iodine (131I) are governed by a complex web of stringent regulations due to its radioactive nature. Compliance with safety standards set by international and national atomic energy authorities requires specialized facilities and rigorous protocols, significantly increasing operational costs. The short half-life of I-131, approximately 8 days, imposes a critical logistical challenge, necessitating a highly efficient and coordinated supply chain from production to end-user administration. Any disruption can lead to product wastage and treatment delays. Furthermore, the licensing process for facilities handling radioactive materials is lengthy and costly, often acting as a barrier to entry for new players and limiting market expansion in certain regions, particularly in developing countries where regulatory frameworks are still evolving.
Additionally, the capital investment for shielded hot cells, radiation monitoring equipment, and staff training represents a substantial financial burden for healthcare providers.
Patient Safety Concerns and Side Effects Present Significant Challenges
While Sodium Iodine (131I) is highly effective, its use is accompanied by notable safety challenges that impact patient acceptance and clinical protocols. The treatment involves exposure to ionizing radiation, which necessitates strict radiation safety measures for patients and healthcare workers to minimize the risk of collateral exposure. Common side effects, such as sialadenitis (inflammation of salivary glands) and transient neck pain, can affect patient quality of life post-treatment. A more serious, though rare, long-term risk is the potential for secondary malignancies, which is a subject of ongoing clinical study and requires careful risk-benefit analysis by clinicians. These concerns can lead to patient apprehension and, in some cases, hesitancy to undergo recommended therapy, potentially affecting treatment adherence and overall market growth.
Other Challenges
Competition from Alternative Therapies
The market faces competition from alternative treatment modalities. For hyperthyroidism, antithyroid drugs (ATDs) like methimazole and surgical options (thyroidectomy) are well-established alternatives. While I-131 offers a definitive treatment, the preference for ATDs or surgery in certain patient demographics, such as pregnant women or those with specific comorbid conditions, segments the addressable market. In thyroid cancer, the development of tyrosine kinase inhibitors (TKIs) and other targeted therapies for advanced or radioactive iodine-refractory disease provides alternative lines of treatment, challenging the dominance of I-131 in the oncological landscape.
Reimbursement and Pricing Pressures
Healthcare cost containment policies and varying reimbursement landscapes across different countries create pricing pressures. The high cost associated with radiopharmaceutical production and the ancillary costs of radiation safety can make I-131 therapy expensive. In regions with constrained healthcare budgets or less comprehensive insurance coverage, reimbursement rates may not fully cover the costs, discouraging healthcare facilities from offering these services and limiting patient access, thereby restraining market potential.
Expansion into Emerging Economies and Product Innovation to Unlock New Growth Avenues
The significant unmet medical need for thyroid disease management in emerging economies presents a substantial growth opportunity. Regions in Asia, Latin America, and the Middle East are experiencing rapid improvements in healthcare infrastructure and rising disposable incomes. The patient population in these areas is large and often underdiagnosed, representing a blue ocean for market penetration. Strategic initiatives by key players, such as joint ventures with local manufacturers and partnerships with regional healthcare providers, can facilitate market entry and build capacity. Furthermore, ongoing research into novel formulations, such as combination therapies or enhanced delivery systems that improve targeting and reduce side effects, holds promise for expanding the clinical applications of I-131 and reinvigorating the market.
Additionally, the growing emphasis on theranostics—the combination of therapy and diagnostics—creates a synergistic opportunity. Using I-123 for diagnostic imaging to precisely identify patients who will benefit most from I-131 therapy allows for a more personalized and efficient treatment approach, optimizing outcomes and resource utilization.
Increased government and private funding for cancer research, with global oncology R&D expenditure exceeding $200 billion annually, is likely to spur further innovation in radiopharmaceuticals, including new applications for established agents like Sodium Iodine (131I).
Sodium Iodine [131I] Capsules Segment Leads the Market Due to Superior Stability and Ease of Handling
The market is segmented based on the formulation type of the radiopharmaceutical into:
Sodium Iodine [131I] Capsules
Sodium Iodine [131I] Oral Solution
Thyroid Cancer Treatment Segment Represents the Largest Application Driven by High Clinical Efficacy
The market is segmented based on its primary therapeutic and diagnostic applications into:
Thyroid Cancer
Hyperthyroidism
Diagnosis and Investigation
Hospitals and Diagnostic Centers Dominate as Key End Users Due to Required Specialized Infrastructure
The market is segmented based on the end users who administer and utilize Sodium Iodine (131I) drugs:
Hospitals
Specialty Clinics and Diagnostic Centers
Cancer Research Institutes
Strategic Maneuvers and Supply Chain Expertise Define the Market Contenders
The competitive landscape of the global Sodium Iodine (131I) Drugs market is characterized by a select group of specialized radiopharmaceutical companies. The market is moderately consolidated, dominated by established players with strong manufacturing capabilities and global distribution networks, particularly in North America and Europe. A key competitive factor is the mastery of the complex supply chain, which is critical due to the short half-life of Iodine-131 (approximately 8 days), demanding precise logistics from production to administration. Players must navigate stringent regulatory frameworks, such as those from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which act as significant barriers to entry.
Jubilant Radiopharma stands as a formidable player, leveraging its extensive radiopharmacy network across North America. Its strength lies in its ability to ensure reliable, just-in-time delivery of essential radiopharmaceuticals to hospitals and clinics, a crucial advantage in this time-sensitive market. Similarly, Mallinckrodt, with its long-standing history in nuclear medicine, holds a significant market position. Its deep expertise and established product portfolio in therapeutic radiopharmaceuticals provide a strong foundation for its Sodium Iodine (131I) drugs business.
Meanwhile, companies like Bracco and BWXT Medical Ltd. are strengthening their positions through vertical integration and technological investments. Bracco's broad imaging and diagnostics portfolio creates synergies, while BWXT leverages its nuclear technology heritage to ensure a stable supply of high-quality isotopes. Their focus on research and development is aimed at improving production efficiency and exploring new therapeutic applications, which is expected to drive future growth.
Furthermore, regional specialists are carving out important niches. In Asia, companies such as Yantai Dongcheng Biochemicals Co.,Ltd. and Chengdu Gaotong Isotope Co.,Ltd. are capitalizing on the rapidly growing healthcare demands in China and surrounding regions. Their growth is propelled by increasing diagnosis rates of thyroid disorders and improving healthcare infrastructure. These companies are expected to gain market share as they expand their regional influence and potentially enter new markets. The competitive dynamics are further influenced by strategic partnerships, where larger entities often collaborate with specialized manufacturers to secure isotope supply and expand their geographic reach.
Jubilant Radiopharma (U.S.)
AnazaoHealth (U.S.)
International Isotopes (U.S.)
Bracco (Italy)
Mallinckrodt (U.K.)
Hta Co., Ltd (South Korea)
Yantai Dongcheng Biochemicals Co.,Ltd. (China)
Chengdu Gaotong Isotope Co.,Ltd. (China)
BWXT Medical Ltd (Canada)
The global Sodium Iodine (131I) Drugs market is experiencing significant momentum, largely propelled by the broader expansion and acceptance of targeted radionuclide therapy (TRT). Unlike traditional systemic treatments, TRT delivers radiation directly to diseased cells, minimizing damage to surrounding healthy tissues. Sodium Iodide I-131 exemplifies this principle, as it is selectively taken up by thyroid tissue due to the sodium-iodide symporter (NIS) protein. This targeted approach results in a high therapeutic index, making it a cornerstone for treating thyroid conditions. The market, valued at approximately 28.2 million USD in 2024, is projected to grow to 45.1 million USD by 2032, reflecting a compound annual growth rate (CAGR) of 7.1%. This growth is heavily supported by an increasing global prevalence of thyroid disorders, with an estimated 200 million people worldwide affected by some form of thyroid disease. Furthermore, advancements in nuclear imaging, such as Single-Photon Emission Computed Tomography (SPECT), allow for precise pre-therapy dosimetry and post-treatment monitoring, enhancing the efficacy and safety profile of I-131 treatments and solidifying its role in modern therapeutic regimens.
Rising Prevalence of Thyroid Cancer and Hyperthyroidism
A primary driver for the Sodium Iodine (131I) Drugs market is the steadily increasing incidence of thyroid cancer and hyperthyroidism globally. Thyroid cancer is among the most rapidly increasing cancer types in many countries, with diagnosis rates having tripled over the past three decades. For instance, in the United States alone, over 40,000 new cases of thyroid cancer are diagnosed annually. Sodium Iodide I-131 is a critical component of the standard-of-care treatment protocol following thyroidectomy (surgical removal of the thyroid gland) for many forms of thyroid cancer. This ablation therapy destroys any remaining thyroid tissue, significantly reducing the risk of recurrence. Similarly, for hyperthyroidism conditions like Graves' disease, I-131 therapy offers a non-surgical, highly effective alternative to antithyroid medications, with success rates often exceeding 90%. This growing patient pool, coupled with high treatment efficacy, creates a sustained and expanding demand for these radiopharmaceuticals.
The market is also being shaped by significant technological advancements in radiopharmaceutical production and handling. Innovations in isotope production, including more efficient nuclear reactors and cyclotrons, are improving the reliability and purity of I-131 supply. Concurrently, developments in automated dispensing systems and shielded vial technology are enhancing safety for healthcare workers and simplifying the administration process in clinical settings. On the regulatory front, agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established clearer pathways for the approval of radiopharmaceuticals, which encourages investment and innovation. Recent years have seen collaborative initiatives between regulatory bodies and industry players to standardize quality control measures and streamline the supply chain for short-lived isotopes. These efforts are crucial for ensuring consistent product availability and maintaining the high standards required for patient safety, thereby supporting market stability and growth.
North America
The North American market is a sophisticated and mature regional segment, largely propelled by a high prevalence of thyroid disorders, particularly thyroid cancer, and a well-established healthcare infrastructure. The United States accounts for the dominant share, driven by advanced diagnostic capabilities and robust insurance coverage. The market is characterized by its stringent regulatory oversight from bodies like the U.S. Food and Drug Administration (FDA), ensuring high safety and efficacy standards, which, while assuring quality, can lead to extended approval timelines for new suppliers. Key market players such as AnazaoHealth and Mallinckrodt have a strong foothold. The region is also a hub for clinical research, with ongoing trials exploring novel theranostic applications of I-131. However, the market faces challenges from high treatment costs and increasing competition from alternative therapies like tyrosine kinase inhibitors for advanced thyroid cancer, which may slightly temper growth in specific patient segments.
Europe
Europe represents another highly developed market for Sodium Iodine (131I) drugs, supported by universal healthcare systems in many of its member states and a growing geriatric population susceptible to thyroid conditions. The regulatory framework, governed by the European Medicines Agency (EMA), is rigorous and harmonized across the continent, emphasizing patient safety. This has encouraged the presence of major international players like Bracco. Market dynamics are influenced by healthcare budgeting and cost-containment policies from national governments, which can impact pricing and reimbursement for radiopharmaceuticals. While Western European nations like Germany, France, and the U.K. demonstrate steady demand, there is significant growth potential in Eastern Europe as healthcare access improves. A key trend across the region is the integration of nuclear medicine with advanced imaging techniques for more precise diagnosis and treatment planning for thyroid diseases.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for Sodium Iodine (131I) drugs globally, projected to witness the highest Compound Annual Growth Rate (CAGR). This explosive growth is fueled by a massive population base, increasing awareness and diagnosis of thyroid disorders, and rapidly expanding healthcare infrastructure. China and India are the primary growth engines, with their governments investing heavily in modernizing medical facilities. The high incidence of goiter and thyroid cancer in certain populations within the region further drives demand. While the market is cost-sensitive, leading to the prominence of local manufacturers like Yantai Dongcheng Biochemicals Co.,Ltd. and Chengdu Gaotong Isotope Co.,Ltd., there is a parallel trend of rising adoption of international standards and products. The primary challenges include disparities in healthcare access between urban and rural areas and varying levels of regulatory maturity across different countries.
South America
The South American market for Sodium Iodine (131I) drugs is emerging and presents a mixed landscape. Countries like Brazil and Argentina have relatively developed healthcare systems with specialized nuclear medicine centers, creating a steady demand for thyroid cancer and hyperthyroidism treatments. Market growth is supported by gradual economic development and increasing healthcare expenditure. However, the region faces significant headwinds, including economic volatility, which can affect government health budgets and patient affordability. Regulatory frameworks are present but can be inconsistent and subject to bureaucratic delays, hindering the swift introduction of new products or suppliers. While international companies are present, the market opportunity is often tempered by these economic and regulatory constraints, making growth more incremental compared to the Asia-Pacific region.
Middle East & Africa
This region exhibits a nascent but promising market for Sodium Iodine (131I) drugs. Growth is primarily concentrated in wealthier Gulf Cooperation Council (GCC) countries such as Saudi Arabia, the UAE, and Israel, which boast advanced medical infrastructure and high healthcare spending. These nations are actively importing advanced radiopharmaceuticals to cater to both local and medical tourism patients. In contrast, much of Africa faces substantial challenges, including limited access to nuclear medicine facilities, a shortage of specialized healthcare professionals, and constrained funding. The market's overall development is therefore highly uneven. Nonetheless, with increasing urbanization, rising health awareness, and gradual infrastructure projects, the long-term potential for market expansion is significant, though it will require sustained investment and international partnership.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Jubilant Radiopharma, AnazaoHealth, International Isotopes, Bracco, Mallinckrodt, and BWXT Medical Ltd, among others.
-> Key growth drivers include the rising global prevalence of thyroid disorders, technological advancements in radiopharmaceuticals, and increased healthcare investment.
-> North America is the dominant market, while Asia-Pacific is projected to be the fastest-growing region during the forecast period.
-> Emerging trends include increased R&D for targeted radionuclide therapy, strategic collaborations for production capacity, and advancements in nuclear medicine imaging.
